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Abstract
Endomorphin-1 is a novel endogenous opioid peptide with high affinity and selectivity for the m-opioid receptor. Earlier results have
shown that it causes antinociception in different pain tests, but its effect is short-lasting. The purpose of the present study was to investigate
the antinociceptive potency of continuously administered endomorphin-1 on carrageenan-induced thermal hyperalgesia by means of a paw
withdrawal test in awake rats. The possible interaction between endomorphin-1 and the C-terminal octapeptide of the novel endogenous
peptide nocistatin (bPNP-3-8P) was examined in the same experimental set-up. Continuous administration of endomorphin-1 (0.1, 0.3, 1 or
2 mg/min for 60 min) did not influence the paw withdrawal latencies of the normal paws. On the inflamed side, endomorphin-1 dose-
dependently decreased the thermal hyperalgesia during continuous administration. The cessation of administration resulted in a gradual
decrease in the antinociceptive effect of endomorphin-1. bPNP-3-8P (0.003–30 mg, administered cumulatively) significantly decreased the
heat hyperalgesia at higher doses (3 and 30 mg). Continuous administration of bPNP-3-8P (0.03, 0.1 and 1 mg/min) did not potentiate the
antinociceptive effect of endomorphin-1; instead, it even shortened the duration of its effect. The results demonstrate that continuous
administration of endomorphin-1 is an effective method of inhibiting thermal hyperalgesia in rats. Furthermore, the fragment bPNP-3-8P
itself has low antinociceptive potency and does not potentiate the antinociceptive effect of endomorphin-1 under these circumstances.
q 2001 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Chronic pain caused by inflammation is known to be
clinically associated with hyperalgesia. Carrageenan-
induced inflammatory hyperalgesia has been widely used
as an animal model to study the mechanism of nociception
and to screen for anti-inflammatory drugs. It has been shown
that peripheral inflammatory hyperalgesia is due, at least in
part, to the enhancement of synaptic transmission mediated
by substance P and excitatory amino acids in the spinal
dorsal horn (Ren et al., 1992; Traub, 1996). The dorsal
horn constitutes the first relay station for incoming somato-
sensory information, and many substances (including
peptides) are involved in the modulation of pain information
at this level. Two tetrapeptides, endomorphin-1 and endo-
morphin-2 (Tyr-Pro-Trp-Phe-NH2 and Tyr-Pro-Phe-Phe-
NH2, respectively), have been identified as endogenous
ligands of the m-opioid receptors (Zadina et al., 1997).
They activate these receptors with high affinity and selec-
tivity (Zadina et al., 1997). Since morphine and other
opiates produce their analgesic effects primarily through
the m-opioid receptor, endomorphins may represent a
class of endogenous opioids that have therapeutic potential.
The presence of a dense aggregation of endomorphin-like
immunoreactive elements in the superficial dorsal horns of
the medulla and spinal cord indicates that endomorphins are
likely to modulate nociceptive transmission (Martin-Schild
et al., 1997; Wu et al., 1999). There is behavioural evidence
that these peptides produce potent analgesia in rodents
under different pain conditions such as acute, inflammatory
and neuropathic pain models (Horvath, 2000). The data
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concerning the duration of their action are somewhat contro-
versial. Some studies found long-lasting antinociception
(Zadina et al., 1997; Wang et al., 1999a,b), while others
reported a short-lasting effect of endomorphin-1 which
had disappeared completely 15–30 min following adminis-
tration (Stone et al., 1997; Horvath et al., 1999; Mizoguchi
et al., 1999; Bhatia et al., 2000; Grass et al., 2000; Soignier
et al., 2000). This short course of action suggests a rapid
degradation in the spinal cord, although the results in this
respect are controversial (Shane et al., 1999; Pe´ter et al.,
1999; Sugimoto-Watanabe et al., 1999). The short-lasting
effect of endomorphins might inhibit their introduction in
human pain therapy. One possibility whereby this phenom-
enon might be overcome is the continuous administration of
the drug. The primary goal of the present study was to assess
the antinociceptive effect of endomorphin-1 during contin-
uous intrathecal administration.
Another recently discovered endogenous peptide that has
been implicated in the modulation of pain transmission is
nocistatin (a heptadecapeptide), produced by the proteolytic
cleavage of prepronociceptin. Prepronociceptin is also the
parent substance of nociceptin, the endogenous ligand for
the opioid-receptor-like receptor (Okuda-Ashitaka et al.,
1998). The name nocistatin originates from observations
that it prevents or reverses the activity of nociceptin in
several (but not all) in vivo and in vitro assays (Okuda-
Ashitaka et al., 1998; Nicol et al., 1998; Hiramatsu and
Inoue, 1999; Ha¨bler et al., 1999; Connor et al., 1999).
Nocistatin is widely present in the brain and the spinal
cord (Okuda-Ashitaka and Ito, 2000), and it presumably
acts as a neuromodulator in spinal pain processing, since
it blocks the hyperalgesia and allodynia induced by noci-
ceptin or prostaglandin-E2 (Okuda-Ashitaka et al., 1998).
Okuda-Ashitaka et al. (1998) have shown that the C-term-
inal octapeptide of nocistatin (Glu-Ile-Glu-Gln-Lys-Gln-
Leu-Gln ¼ bPNP-3-8P) has similar biological activity to
that of the heptadecapeptide in inhibiting nociceptin-
induced allodynia, and this fragment is crucial for the activ-
ity. Since the only two studies of the effect of this fragment
furnished opposite results (Okuda-Ashitaka et al., 1998; Xu
et al., 1999), the second goal of the present study was to
determine the antinociceptive potency of bPNP-3-8P on
carrageenan-induced hyperalgesia.
There are also few results which suggest an interaction
between nociceptin and endomorphins (Wang et al.,
1999a,b). Since nocistatin antagonizes the effect of noci-
ceptin, and the above-mentioned findings strongly suggest
that both nocistatin and the endomorphins are involved in
spinal pain transmission, there is a possibility for an inter-
action between the endogenous opioid, endomorphin-1 and
nocistatin. Few data are available on the possible interac-
tion between the opioid system and nocistatin until now
(Zhao et al., 1999; Nakano et al., 2000), and none on the
interaction of endomorphin-1 with bPNP-3-8P. The third
goal of our study was therefore to analyze the possible
interaction of continuously administered endomorphin-1
and bPNP-3-8P on an inflammatory pain model at the
spinal level.
2. Methods
2.1. Animals
Animal surgery and testing were approved by the institu-
tional animal care committee of the University of Szeged
Faculty of Medicine. Male Wistar rats ðn ¼ 131Þ weighing
302.6 ^ 2.71 g were used in the experiments. The rats were
anaesthetized with ketamine and xylazine (72 and 8 mg/kg
intraperitoneally, respectively). An intrathecal catheter (PE-
10 tubing) was inserted via the cisterna magna and passed
8.5 cm caudally. The skin incision was closed, leaving 2 cm
of the catheter free above the skull. The rats were allowed to
recover for at least 4 days before testing. Animals exhibiting
any postoperative neurological impairment were excluded
from the study. All experiments were carried out during the
same period of the day in order to exclude diurnal variations
in pharmacologic effects. At the end of the study, the
animals were killed with an overdose of pentobarbital, and
methylene blue was injected intrathecally to evaluate the
position of the catheter. The animals were randomly
assigned to treatment groups (n ¼ 5–11 per group), and
the observer was blind to the treatment administered.
2.2. Drugs
The following drugs were administered: ketamine hydro-
chloride (Ketalar; Parke-Davis, Vienna, Austria), xylazine
(Rompun TS; Bayer AG, Leverkusen, Germany), and carra-
geenan lambda (Sigma-Aldrich Kft., Budapest, Hungary).
Endomorphin-1 and bPNP-3-8P were synthesized by a
solid-state method and purified by means of HPLC in the
Isotope Laboratory of the Biological Research Center of the
Hungarian Academy of Sciences. The peptide solutions in
sterile physiological saline were freshly prepared on the day
of the experiment.
In the series involving bPNP-3-8P administration alone,
the drug or saline was injected intrathecally at a volume of
5 ml over 30 s, followed by a 10 ml flush of physiological
saline. Since only a few data are available about bPNP-3-8P
– for the sake of getting the effective dose – we used a very
wide dose intervallum and in this case the drug was applied
cumulatively (0.003–30 mg) every 30 min.
In the further series when the endomorphin-1 and bPNP-
3-8P were administered continuously, the animals were
connected to a microinjection syringe pump (2Biological
Instruments) via calibrated tubing. Drugs were injected at
a volume of 60 ml, followed by 10 ml of saline to wash the
catheter. Drugs were injected at a flow rate of 1 ml/min. The
control group received saline intrathecally.
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2.3. Inflammatory pain test (paw withdrawal test)
The rats were placed on a glass surface in a plastic cham-
ber and were allowed to acclimatize to their environment for
15–30 min before testing, and the baseline hindpaw with-
drawal latencies (pre-carrageenan baseline values at
2180 min) were obtained. The heat stimulus was directed
onto the plantar surface of each hindpaw. The cut-off time
was set at 20 s to avoid tissue damage. A detailed descrip-
tion of this method has been published elsewhere
(Hargreaves et al., 1988). Unilateral inflammation was
induced by intraplantar injection of 1.5 mg carrageenan in
0.1 ml physiological saline into one of the hindpaws. The
paw withdrawal latencies were obtained again 3 h after
carrageenan injection (post-carrageenan baseline values at
0 min) and at 10 min intervals afterwards for 130 min.
2.4. Experimental paradigm
2.4.1. Dose–response curves for single drugs
The first series of experiments was performed to deter-
mine the dose–response effect of endomorphin-1 (0.1, 0.3, 1
and 2 mg/min, continuous administration, total dose: 6, 18,
60 and 120 mg during 60 min) and bPNP-3-8P (0.003–0.03–
0.3–3–30 mg/5 ml, cumulative administration).
2.4.2. Drug interaction
The second series of experiments was performed with
different doses of endomorphin-1 and bPNP-3-8P in order
to determine the possible antinociceptive interaction of the
two drugs. In this series, both bPNP-3-8P (0.03, 0.1 and
1 mg/min) and endomorphin-1 (0.1, 0.3, 1 and 2 mg/min)
were administered continuously and simultaneously.
2.5. Data analysis
Data are presented as means ^ SEM. Data sets were
examined by analyses of variance (ANOVA) with repeated
measures. The area under the curve (AUC) values were
obtained by calculating the area during drug administration
(10–60 min) and after drug administration (100–130 min).
These data sets were examined by one-way ANOVA. The
significance of differences between experimental and
control values was calculated by using the LSD post hoc
test. A P-value of less than 0.05 was considered significant.
3. Results
Before the microinfusion, the mean paw withdrawal
latency was 10.05 ^ 0.09 s and did not differ significantly
between the groups. The intraplantar injection of carragee-
nan reduced the nociceptive threshold of the treated paw
significantly to 3.07 ^ 0.12 s ðP , 0:05Þ, indicating hyper-
algesia. This hyperalgesia persisted throughout the investi-
gation in the saline-treated group (Fig. 1A).
3.1. Single drug administration
3.1.1. Endomorphin-1
None of the administered doses of endomorphin-1 chan-
ged the paw withdrawal latencies on the non-inflamed side
significantly, although the highest dose tended to increase it
(Fig. 1B,E). The lowest dose of endomorphin-1 did not
cause a significant increase in the paw withdrawal latencies
on the inflamed side as compared to the post-carrageenan
values. The higher doses caused significant increases in the
paw withdrawal latencies at several time points, although
significant differences from the baseline values were
observed at almost all time points, suggesting that the
hyperalgesia was merely decreased, but not relieved. Analy-
sis of the AUC data revealed that the hyperalgesia decreased
dose-dependently in the 10–60 min interval, although 2 mg/
min was less effective than 1 mg/min, suggesting the devel-
opment of a ceiling effect (Fig. 2E). The cessation of admin-
istration resulted in a gradual decrease in the paw
withdrawal latencies (Fig. 1B,E), though analysis of the
AUC values revealed significant differences between the
control and the 0.3 or 1 mg/min endomorphin-1-treated
group in the period 100–130 min (Fig. 2F).
3.1.2. bPNP-3-8P
bPNP-3-8P at higher doses (0.3–30 mg) significantly
increased the paw withdrawal latencies for the inflamed
hindpaws as compared to the post-carrageenan values
(Fig. 1F). There were no signs of motor impairment.
3.2. Drug interaction
None of the doses of bPNP-3-8P influenced significantly
the antinociceptive effect of endomorphin-1 during the infu-
sion (Fig. 2). After the cessation of administration, the AUC
values showed that bPNP-3-8P shortened the antinocicep-
tive effect of 1 mg/min endomorphin-1 (Fig. 2F). No treat-
ment caused any motor impairment.
4. Discussion
The most important finding from our study is the potent
antihyperalgesic effect of endomorphin-1 during continuous
administration on this inflammatory pain model in rat. The
continuous infusion of endomorphin-1 caused dose-depen-
dent antinociception, and the termination of endomorphin-1
delivery was followed by a gradual decrease in its effect.
bPNP-3-8P in high doses decreased the inflammation-
induced heat hyperalgesia, it did not potentiate the antino-
ciceptive effect of endomorphin-1; instead, it even shor-
tened the duration of its effect.
4.1. Endomorphin-1
The potent and selective activity of the endomorphins at
the m-opioid receptor has led to the suggestion that this may
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lead to the development of new analgesics with less addic-
tive properties than those of the traditional opioid receptor
agonists. It has been reported that endomorphins exert an
antinociceptive effect in different pain tests, although the
potencies of the drugs largely depend on the species, on
the applied pain tests and on the routes of administration
(Zadina et al., 1997; Loh et al., 1998; Yamaguchi et al.,
1998; Przewlocka et al., 1999; Sanchez-Blazquez et al.,
1999a,b). Some differences from morphine have also been
observed, i.e., Przewlocka et al. (1999) found that endomor-
phins displayed weaker analgesic effects than that of
morphine on the formalin-induced pain response in both
phases in rats after intrathecal administration. Thus, endo-
morphins appeared to be less potent than morphine in antag-
onizing inflammatory pain, but unlike morphine, they
displayed strong analgesic activity against neuropathic
pain. These effects of endomorphins contrast with the
previous observations that the analgesic efficacy of opioids
is increased in inflammation and reduced in neuropathic
pain (Ossipov et al., 1999). It has been postulated that differ-
ent m-opioid receptor subtypes may mediate the effects of
morphine and endomorphins in neuropathic pain or that the
molecular characteristics of the m-opioid receptors are
modified by nerve injury (Przewlocki et al., 1999).
However, a recent study suggested that this may depend
on the type of nerve injury, because the sensitivity to endo-
morphin-2 was reduced in rats exhibiting ongoing neuro-
pathic pain-like behaviour after peripheral axotomy, and
furthermore endomorphin-2 depressed the flexor reflex
after carrageenan-induced inflammation (Grass et al.,
2000). Our study demonstrated that continuous intrathecal
administration of endomorphin-1 significantly decreased,
but did not reverse, the inflammation-induced thermal
hyperalgesia and it had no significant effect on the nocicep-
tive threshold of the non-inflamed side at the doses used in
this study.
There is some controversy concerning the data on the
duration of action of endomorphins. Zadina et al. demon-
strated that endomorphin-1 causes prolonged analgesia
(mice, intracerebroventricular): about half of the animals
were still analgesic 1 h after the administration of high
doses (10–20 mg). Essentially identical results were
obtained by Przewlocka et al. (1999) in both thermal and
mechanical pain tests in rats after intrathecal administration
and by Wang et al. (1999) (intracerebroventricular or
intrathecal) in the tail-flick test. In contrast, several studies
revealed that the antinociception was short-lasting, i.e. it
was completely absent 15–30 min following intracerebro-
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Fig. 1. Time course of the antinociceptive effects of different doses of endomorphin-1 ((B) 0.1, (C) 0.3, (D) 1 and (E) 2 mg/min), bPNP-3-8P (F) and saline-
treated control group (A). The horizontal line on the x-axis marks the period of drug administration, " shows the initiation of the microinfusion and # shows its
termination. In the last figure (F) the arrows indicate the injection of the cumulatively administered bPNP-3-8P; the applied doses are written below the x-axis
under each arrow. Each point represents the means ^ SEM of the result on five to 11 animals. The symbol * indicates significant ðP , 0:05Þ difference between
the data point and the post-carrageenan baseline value. The symbol X indicates a non-significant difference between the data point and the pre-carrageenan
baseline value.
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Fig. 2. Time course of the antinociceptive effect of different doses of endomorphin-1 ((A) 0.1, (B) 0.3, (C) 1 and (D) 2 mg/min) in combination with bPNP-3-
8P. The horizontal line on the x-axis marks the period of the drug administration, " shows the initiation of the microinfusion and # shows its termination. The
magnitude of the dose-dependent effects of endomorphin-1 alone or with bPNP-3-8P during drug administration (10–60 min) (E) and after its termination
(100–130 min) (F) are presented as AUC values. The symbol * denotes a significant ðP , 0:05Þ difference between the data point and the result for the control
group (without any drug treatment). The symbol £ and the connecting lines indicate significant differences between 1 mg/min endomorphin-1 by itself and the
combination treatment. Values represent the means ^ SEM of the data on five to 11 animals.
ventricular or intrathecal injection (Stone et al., 1997;
Horvath et al., 1999; Mizoguchi et al., 1999; Sakurada et
al., 1999; Bhatia et al., 2000; Grass et al., 2000; Soignier et
al., 2000). The short course of action suggests that the
peptides may be broken down rapidly in the spinal cord.
Endomorphins are small peptides, consisting of only four
amino acids, which makes them vulnerable to rapid degra-
dation by peptidases. The metabolic fate of endomorphins
either in vitro or in the organism remains relatively unclear.
It has been shown that dipeptidyl peptidase IV, a membrane-
bound serine proteinase, plays a significant role in endomor-
phin-2 degradation, since endomorphin-2 was proved to be
an excellent substrate for this enzyme in an in vitro assay,
and a dipeptidyl peptidase IV inhibitor potentiates the
analgesic actions of endomorphin-2 (Shane et al., 1999).
In contrast, Ro´nai et al. (1999) found that another dipeptidyl
aminopeptidase IV inhibitor – Diprotin A – neither poten-
tiated nor prolonged the effect of endomorphin-1. A recent
paper reported that the total in vitro degradation of endo-
morphin-1 requires more than 1 h (Pe´ter et al., 1999); simi-
larly, Sugimoto-Watanabe et al. (1999) found a slow
degradation of endomorphin-1. These results support the
notion that endomorphins are metabolized by the brain
tissue, though the dynamics of the in vivo degradation
remains unknown. Another possible explanation for the
short-lasting effect of endomorphins could be that the m-
opioid receptor is internalized from the membrane to the
internal side of the cell by endocytosis after activation by
the endomorphins (Burford et al., 1998; McConalogue et al.,
1999). Our results do not support this possibility, because m-
opioid receptors have been shown to be continuously
antero- and retrogradely transported, which could indicate
a continual turnover of the receptor, resulting in the efficacy
of endomorphin-1 during the continuous administration (Ji
et al., 1995).
4.2. Nocistatin/bPNP-3-8P
Studies on nocistatin have indicated that it presumably
acts as a neuromodulator in spinal pain processing.
Although the nocistatin binding site has not been identified
yet, it has been shown that it binds to the membrane of the
mouse brain and spinal cord with high affinity (Okuda-Ashi-
taka et al., 1998). In pain transmission, nocistatin is reported
to have different effects, including analgesia, no effect and
nociception, depending on the animal species tested, applied
doses, the route of administration and so on. Sakuda et al.
observed that nocistatin blocks the thermal hyperalgesia and
mechanical allodynia induced by nociceptin or prostaglan-
din-E2 in mice after intrathecal administration (Okuda-Ashi-
taka et al., 1998). Nocistatin also attenuated the
inflammatory mechanical hyperalgesia induced by carra-
geenan/kaolin (Nakagawa et al., 1999) and reversed the
nociceptin-induced inhibition of morphine analgesia in
rats after intracerebroventricular administration (Zhao et
al., 1999), while it had no effect in acute heat pain tests
(hot-plate, tail-flick) (Okuda-Ashitaka et al., 1998; Zhao et
al., 1999; Yamamoto and Sakashita, 1999; Zeilhofer et al.,
2000). There are some opposite results too, e.g. Xu et al.
(1999) observed a facilitatory effect on the flexor reflex in
anaesthetized decerebrated rats. While Yamamoto and
Sakashita (1999) and Nakano et al. (2000) reported the anti-
nociceptive effect of nocistatin in the formalin test, Zeilho-
fer et al. (2000) found that nocistatin dose-dependently
increased the number of flinches during both phases of
formalin-induced pain.
To date only a few data have been published on the
cellular mechanisms of nocistatin. Zeilhofer et al. (2000)
have shown that nocistatin reduces inhibitory glycinergic
and GABAergic synaptic transmission in the spinal cord
dorsal horn via a presynaptic mechanism involving Gi/o-
proteins, but leaves the excitatory glutamatergic transmis-
sion unaffected. The results suggest that nocistatin is
released from such local interneurons onto the presynaptic
terminals of inhibitory neurons. It is still not known under
what physiological or pathophysiological conditions these
peptides are released.
It has been shown that the C-terminal octapeptide of
nocistatin, which is conserved in bovine, human and
mouse species, appears to be the minimal essential core
for biological affinity. It has been reported that the octapep-
tide bPNP-3-8P is as potent as the parent peptide in the
inhibition of nociceptin-induced allodynia (Okuda-Ashitaka
et al., 1998). However, Xu et al. (1999) did not find a
significant effect of this octapeptide (7 and 70 ng), whereas
we observed the significant effects of much higher doses of
this octapeptide than those described by Okuda-Ashitaka et
al. (1998). These discrepancies might be due to the differ-
ences between the species and/or the pain tests.
4.3. Interaction
Only a few interaction studies have been carried out on
endomorphin with respect to antinociception. It has been
observed that nociceptin potentiates or inhibits endomor-
phin-1-induced antinociception, depending on the route of
administration: intracerebroventricular co-administration
inhibits, while intrathecal co-administration synergizes the
antinociceptive effects of endomorphin-1 (Wang et al.,
1999a,b). Isobolographic analysis of the interaction between
intrathecally administered endomorphin-1 and lidocaine
revealed that concomitant administration of the two drugs
produces synergistic suppression of the phase-2 behavioural
response in the rat formalin test (Hao et al., 1999). A recent
article proposed potentiated antinociception after co-admin-
istration of the a2-adrenoceptor agonist clonidine and endo-
morphin-1 at the spinal level (Hao et al., 2000).
Both nocistatin-like and endomorphin-like immunoreac-
tivities are present in the superficial laminae (I–II) of the
dorsal horn (Martin-Schild et al., 1997; Okuda-Ashitaka et
al., 1998; Wu et al., 1999). The similar patterns of their
distribution in the spinal cord theoretically suggest some
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kind of interaction. Recent studies have shown that nocis-
tatin (0.005–500 ng) does not affect morphine-induced
analgesia after intrathecal administration, whereas it
reversed the antagonistic effect of OFQ on morphine analge-
sia (doses of 0.05–500 ng) in a bell-shaped manner (Zhao et
al., 1999). Furthermore, the classical opioid system did not
participate in the analgesic action of nocistatin in the mouse
formalin test at the spinal level, because naloxone did not
influence the antinociceptive effect of nocistatin in the
formalin test (Nakano et al., 2000). Our results are in agree-
ment with these data, suggesting that there is no potentiating
effect of the C-terminal octapeptide of nocistatin on endo-
morphin-1-induced antinociception in the rat thermal hyper-
algesia model.
4.4. Summary
Administration of endogenous peptides might be accom-
panied by several advantages; since they are endogenous
ligands, they have their own cleavage enzymes, and they
have lower toxicity. The short-lasting effect of endomor-
phin-1 and the low permeability of the blood–brain barrier
for peptides suggest that the possible therapeutic role of
endomorphins might lie in their continuous local adminis-
tration peripherally or centrally. Our results suggest that this
mode of application is a very effective method, since it dose-
dependently and significantly decreased the heat-hyperalge-
sia, and after cessation of the infusion the observed antino-
ciceptive effect decreased. Thus, endomorphin-1 may be a
novel and useful anti-hyperalgesic drug at the spinal level.
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